Theriva Biologics Announces Outcome Of Data And Safety Monitoring Committee Review In Phase 1b/2a Clinical Trial Of SYN-004 In Allogeneic Hematopoietic Cell Transplant Recipients; The DSMC Has Recommended That The Study Proceed To Enroll Cohort 3
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics announced a positive review from the Data and Safety Monitoring Committee for its Phase 1b/2a trial of SYN-004 in preventing acute graft-versus-host-disease in transplant recipients. The study will proceed to enroll Cohort 3.
October 03, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theriva Biologics' SYN-004 trial receives a positive DSMC review, allowing the study to proceed to the next cohort. This indicates potential progress in their clinical development pipeline.
The DSMC's recommendation to proceed to Cohort 3 suggests that the trial is meeting safety and pharmacokinetic expectations, which is a positive indicator for the drug's development. This progress could boost investor confidence in Theriva Biologics' pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100